Amplia Therapeutics Reports Promising Results in Pancreatic Cancer Trial: 16 Partial Responses Confirmed in ACCENT Trial

Amplia Therapeutics has reported promising results in its ACCENT trial for pancreatic cancer, with 16 confirmed partial responses out of 55 patients, indicating a 29% objective response rate. This could enhance the company's position in the oncology sector and strengthen its focus on developing Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Amplia Therapeutics Limited (ASX:ATX) has made significant strides in its fight against pancreatic cancer, as evidenced by promising results from its ACCENT trial. The trial, which focused on Focal Adhesion Kinase (FAK) inhibitors, reported 16 confirmed partial responses out of 55 patients, translating to a 29% objective response rate [1]. This outcome underscores the potential of Amplia's approach and could bolster its position in the oncology sector.

The ACCENT trial's success aligns with broader advancements in pancreatic cancer treatment. Concurrently, Tango Therapeutics (TNGX) has initiated a Phase 1/2 clinical trial combining its investigational drug TNG462 with Revolution Medicines' RAS inhibitors, daraxonrasib or zoldonrasib, to treat patients with MTAP-deleted and RAS-mutant metastatic pancreatic or lung cancer [2]. This trial aims to evaluate the safety, pharmacokinetics, and antitumor activity of the combined therapy, which capitalizes on the strong preclinical evidence for TNG462 in combination therapies.

Adding to the momentum, Novocure, another key player in pancreatic cancer treatment, has announced that it will present additional secondary endpoint data from its Phase 3 PANOVA-3 trial at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2025 [3]. The data, which includes quality of life outcomes and a post-hoc analysis of time to first opioid use, will further contribute to the understanding of Tumor Treating Fields (TTFields) therapy's efficacy in treating unresectable, locally advanced pancreatic cancer.

These developments highlight a growing trend in the oncology sector, where innovative therapies and combination treatments are showing promise in combating pancreatic cancer. Amplia Therapeutics' progress in the ACCENT trial, along with the ongoing efforts of Tango Therapeutics and Novocure, underscores the potential for significant advancements in pancreatic cancer treatment.

References:
[1] https://www.listcorp.com/asx/atx/amplia-therapeutics-limited/news/amplia-one-step-closer-in-the-fight-against-pancreatic-cancer-3206838.html?ref=more_news
[2] https://www.gurufocus.com/news/2949957/tango-therapeutics-announces-first-patient-dosed-in-phase-12-trial-of-tng462-plus-revolution-medicines-daraxonrasib-or-zoldonrasib-in-patients-with-rasmutant-mtapdeleted-pancreatic-or-lung-cancer
[3] https://www.marketscreener.com/quote/stock/NOVOCURE-LIMITED-24157014/news/Novocure-to-Present-Final-Secondary-Endpoint-Data-from-the-Phase-3-Panova-3-Trial-of-Tumor-Treating-50394125/